Add to ORKGMutations in the Kirsten Ras 1 (KRAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) genes may be predictive of response to drugs directly linked to the Epidermal Growth Factor Receptor (EGFR) signaling pathway
Abstract: Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an impor...
OBJECTIVE: RAS proteins control signaling pathways which are the main regulators of the normal cell ...
The prognostic value of KRAS and BRAF mutation in colorectal cancer (CRC) is very consistent. Severa...
Mutations in the Kirsten Ras 1 (KRAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) gene...
Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in...
Gastric cancer (GC) remains a major worldwide health problem and survival rates continue to be poor ...
BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mut...
The RAS gene family, responsible for signal transduction within the mitogen activated protein kinase...
The introduction of KRAS testing as a diagnostic tool to select patients for epidermal growth factor...
Second RAF paralogue (BRAF) is a proto-oncogene that encodes a serine/threonine kinase that transduc...
Molecular diagnostics of human cancers may increase accuracy in prognosis, facilitate the selection ...
AbstractBackgroundEpidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF a...
Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a...
<p>Activating mutations in both BRAF and KRAS will result in EGFR independent cell proliferation and...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
Abstract: Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an impor...
OBJECTIVE: RAS proteins control signaling pathways which are the main regulators of the normal cell ...
The prognostic value of KRAS and BRAF mutation in colorectal cancer (CRC) is very consistent. Severa...
Mutations in the Kirsten Ras 1 (KRAS) and V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) gene...
Somatic mutations in KRAS, NRAS, and BRAF genes are related to resistance to anti-EGFR antibodies in...
Gastric cancer (GC) remains a major worldwide health problem and survival rates continue to be poor ...
BACKGROUND: Epidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF are mut...
The RAS gene family, responsible for signal transduction within the mitogen activated protein kinase...
The introduction of KRAS testing as a diagnostic tool to select patients for epidermal growth factor...
Second RAF paralogue (BRAF) is a proto-oncogene that encodes a serine/threonine kinase that transduc...
Molecular diagnostics of human cancers may increase accuracy in prognosis, facilitate the selection ...
AbstractBackgroundEpidermal growth factor receptor (EGFR) and its downstream factors KRAS and BRAF a...
Activating mutations in KRAS and in one of its downstream mediators, BRAF, have been identified in a...
<p>Activating mutations in both BRAF and KRAS will result in EGFR independent cell proliferation and...
Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti- epiderma...
Abstract: Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an impor...
OBJECTIVE: RAS proteins control signaling pathways which are the main regulators of the normal cell ...
The prognostic value of KRAS and BRAF mutation in colorectal cancer (CRC) is very consistent. Severa...